Lifecore Biomedical, Inc. (LFCR): Revenue
$128.87M
Year ended 2025-05-25
+5.0%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-05-25 | $128.87M | +0.5% | 2025-08-07, From 2024-05-27 |
| 2024-05-26 | $128.26M | +24.2% | 2025-08-07, From 2023-05-29 |
| 2023-05-28 | $103.27M | -7.2% | 2024-08-26, From 2022-05-30 |
| 2022-05-29 | $111.27M | +10.3% | 2024-08-26, From 2021-05-31 |
| 2021-05-30 | $100.87M | n/c | 2024-03-20, From 2020-06-01 |
| 2020-05-31 | $160.07M | -71.3% | 2023-03-16, From 2019-05-27 |
| 2019-05-26 | $557.56M | +6.4% | 2021-07-29, From 2018-05-28 |
| 2018-05-27 | $524.23M | +11.6% | 2020-08-14, From 2017-05-29 |
| 2017-05-28 | $469.78M | -1.5% | 2019-08-01, From 2016-05-30 |
| 2016-05-29 | $476.92M | n/a | 2018-08-09, From 2015-06-01 |
| No annual figure between 2013-05-26 and 2016-05-29. | |||
| 2013-05-26 | $441.71M | +39.1% | 2013-08-07, From 2012-05-28 |
| 2012-05-27 | $317.55M | +14.8% | 2013-08-07, From 2011-05-30 |
| 2011-05-29 | $276.73M | +16.2% | 2013-08-07, From 2010-05-31 |
| 2010-05-30 | $238.22M | n/a | 2012-08-08, From 2009-06-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $128.87M | +0.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $125.58M | +13.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $116.59M | +10.2% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $146.07M | +0.6% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $148.87M | +77.1% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $149.50M | -0.3% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $109.79M | +21.4% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $107.46M | +66.9% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $154.90M | +7.4% |
Compare LFCR, XNCR, GYRE, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗